Domainex
Integrated drug discovery services for medicines research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
£120k | Grant | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 61 % | - | - | 24 % | 19 % | 14 % | (15 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 13 % | - | 17 % | 17 % | 15 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 10 % | - | 12 % | 13 % | 12 % | 10 % | (9 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 24 % | - | - | 34 % | - | - | - |
Source: Company filings or news article
Related Content
Domainex is an integrated drug discovery service and contract research organization (CRO) that partners with pharmaceutical and biotechnology companies, academic institutions, and patient foundations. The company was founded in 2001 as a spin-out from University College London, Birkbeck College, and the Institute of Cancer Research. One of its founding technologies was Combinatorial Domain Hunting (CDH), a patented method for expressing challenging protein targets for drug discovery.
The company provides a comprehensive suite of pre-clinical services that span the drug discovery pipeline, from target nomination to the selection of a drug candidate. Its offerings include medicinal, computational, and analytical chemistry, as well as protein expression, structural biology, and a range of cell-based and biochemical assays. Domainex utilizes proprietary platforms such as 'LeadBuilder' for virtual screening and 'FragmentBuilder' for fragment-based drug discovery to identify potential drug hits. The business model operates as a fee-for-service CRO, providing customized scientific solutions to advance its clients' research programs. Its clients include organizations like UCB, St George’s University, and The Institute of Cancer Research.
A significant milestone was the 2006 merger with NCE Discovery, a medicinal chemistry services company. The company has demonstrated consistent growth, expanding its facilities several times and moving to the Chesterford Research Park in 2016 to increase capacity. Further expansion occurred in 2022 with a new facility at Unity Campus. In recognition of its growth in international trade, Domainex received the King's Award for Enterprise in 2023. As of May 2025, Hayley French serves as the Chief Executive Officer.
Keywords: drug discovery, contract research organization, CRO, medicinal chemistry, preclinical research, biotechnology services, protein expression, assay development, structural biology, computational chemistry, fragment-based drug discovery, lead optimization, hit identification, biophysical assays, oncology research, cell biology, molecular biology, bioanalytics, pharmaceutical partnerships, target validation